ArticleJAMA network open2026
Racial and Ethnic Disparities in Medication Adherence Among Medicare Advantage Enrollees With Diabetes.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Importance: Appropriate medication management can prevent adverse outcomes, yet medication nonadherence remains common, including among patients with diabetes. Objective: To examine racial and ethnic disparities in medication adherence among Medicare Advantage (MA) enrollees with diabetes and assess factors contributing to these disparities. Design, Setting, and Participants: Using the Medicare Master Beneficiary Summary File and MA encounter data, this cohort study included MA enrollees with Part D coverage in 2019 and a documented diabetes diagnosis from January 1, 2017, to December 31, 2018, who filled at least 1 prescription for metformin, insulin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in 2019. Analysis was conducted between December 2024 and November 2025. Main Outcomes and Measures: Unadjusted and adjusted disparities in adherence (proportion of days covered ≥80%) during 2019 were examined for insulin, metformin, and SGLT2 inhibitors and/or GLP-1 RAs, distinguishing within-plan disparities from differences between plans serving proportionately more vs fewer Black or Hispanic enrollees. Oaxaca-Blinder decomposition analysis estimated the contribution of covariates to adherence disparities. Results: Among 587 716 total beneficiaries (mean [SD] age, 72.11 [8.85] years), analyses of disparities between Black and White enrollees included 80 586 Black (63.3% female) and 233 505 White (50.9% male) beneficiaries; analyses of disparities between Hispanic and White enrollees included 83 116 Hispanic (53.9% female) and 190 509 White (51.1% male) beneficiaries. In unadjusted analyses, adherence was lower among Black beneficiaries than among White beneficiaries: -9.0 percentage points [pp] for SGLT2 inhibitors and/or GLP-1 RAs, -8.0 pp for insulin, and -10.5 pp for metformin (all P < .001). Adherence was also lower among Hispanic beneficiaries than among White beneficiaries: -8.1 pp for SGLT2 inhibitors and/or GLP-1 RAs, -2.8 pp for insulin, and -3.6 pp for metformin (all P < .001). By medication type, within-plan disparities accounted for 74.6% to 85.3% of adherence disparities between Black and White enrollees and 39.1% to 66.1% of disparities between Hispanic and White enrollees. Medicaid or Low-Income Subsidy enrollment was associated with reductions in disparities between Black and White enrollees (22.0% for insulin and 32.3% for SGLT2 inhibitors and/or GLP-1 RAs) and Hispanic and White enrollees (63.9% for insulin and 41.3% for SGLT2 inhibitors and/or GLP-1 RAs). Conclusions and Relevance: This retrospective cohort study of MA enrollees with diabetes found racial and ethnic disparities in diabetes medication adherence. Disparities in adherence to insulin or SGLT2 inhibitors and/or GLP-1 RAs were partially mitigated by Medicaid and prescription drug subsidies but less so by plan-level factors. The findings suggest that additional insurance- and community-level strategies are needed to improve medication adherence among disadvantaged patients and communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.